Kabra Drugs Secures Letter of Intent from Chhattisgarh Government for ₹200 Crore Pharmaceutical Project
Kabra Drugs Ltd has received a significant Letter of Intent (LOI) from the Government of Chhattisgarh regarding a major proposed investment in the pharmaceutical manufacturing sector. The initiative aims to establish a state-of-the-art facility at Nava Raipur Pharma Park, which is expected to substantially boost the company's operational footprint and support its long-term growth strategy.The LOI was granted following discussions held during the Hyderabad Investors Connect on Friday, July 12, in Hyderabad. The proposed project encompasses the establishment of a pharmaceutical manufacturing facility alongside related healthcare manufacturing activities at Nava Raipur Pharma Park, Chhattisgarh.
This investment is pegged at approximately ₹200 Crore. The venture is anticipated to contribute significantly to local employment, projecting the creation of around 250 direct and indirect jobs. The project is designed not only for expansion but also to strengthen Kabra Drugs' overall manufacturing capabilities in line with its growth trajectory.
The fundamentals of the proposed investment, as confirmed by the company, are detailed below:
| Parameter | Details |
|---|---|
| Authority | Government of Chhattisgarh |
| Project Type | Pharmaceutical and healthcare manufacturing facility |
| Proposed Investment | Approximately ₹200 Crore |
| Location | Nava Raipur Pharma Park, Chhattisgarh |
| Employment Generation | Approximately 250 direct and indirect opportunities |
| Expected Benefits | Expansion of manufacturing capacity and strengthening of operational capabilities |
The proposed investment is contingent upon the successful execution of definitive agreements. Furthermore, the project requires the receipt of various necessary approvals, sanctions, incentives, and compliance as required by relevant authorities over time. The initiative holds the potential to enhance the company's manufacturing scope and support future growth plans upon implementation and regulatory clearances.
Stock Price Movement
At the close of trade on Friday, Kabra Drugs Ltd. settled at ₹23.63, posting a 10.27% gain. The shares moved within their intraday range, tracking between a low of ₹21.75 and a high of ₹25.02.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.